About Seawolf Therapeutics

Seawolf Therapeutics is unlocking the full potential of DNA-based medicines to transform how diseases are addressed. Our proprietary TRIDENT™ technology, a redosable lipid nanoparticle (LNP)-based DNA delivery system, delivers DNA payloads to cells with unparalleled potency and safety to drive robust, sustained expression of therapeutic proteins.

Leadership Team

Liz Alcamo

Elizabeth Alcamo, PhD
President & CEO

Rob Burke, PhD

Rob Burke, PhD
Chief Scientific Officer

Ramon

Ramon Diaz Trelles
Head of Payload Engineering

Melissa Gutierrez

Melissa Gutierrez
Head of Facilities

Amit Sagi

Amit Sagi
Head of Delivery Technologies

Laura Smith

Laura Smith
Head of Development Sciences

Board Members and Observers

Tom Woiwode, PhD

Tom Woiwode, PhD (chair)
Managing Director, Versant Ventures

Liz Alcamo

Elizabeth Alcamo, PhD
President & CEO,
Seawolf Therapeutics

Laura Brass, PhD, MBA

Laura Brass, PhD, MBA
Managing Director,
Novartis Venture Fund

Adam Cotton, PhD, MBA

Adam Cotton, PhD, MBA (observer)
Associate, Novartis Venture Fund

Daniel Faga, MBA

Daniel Faga, MBA
President & CEO, Anaptys Bio

Todd Foley, MBA

Todd Foley, MBA
Managing Director,
MPM BioImpact

Ritikesh Kumar, MBA (observer)
CRISPR Therapeutics

Ben Yaden, PhD (observer)
Eli Lilly Corporation

Investors

Versant Logo
BioImpact Logo
Eli Lilly and Company